Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.26 USD
-0.13 (-2.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.19%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Travere Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 145 | 212 | 227 | 198 | 175 |
Cost Of Goods | 11 | 8 | 7 | 6 | 5 |
Gross Profit | 134 | 204 | 221 | 192 | 170 |
Selling & Adminstrative & Depr. & Amort Expenses | 522 | 471 | 382 | 368 | 307 |
Income After Depreciation & Amortization | -388 | -267 | -162 | -176 | -137 |
Non-Operating Income | 23 | 0 | 2 | 6 | 10 |
Interest Expense | 11 | 11 | 20 | 19 | 19 |
Pretax Income | -376 | -278 | -180 | -189 | -146 |
Income Taxes | 0 | 0 | 0 | -19 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -376 | -278 | -180 | -169 | -146 |
Extras & Discontinued Operations | 265 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -111 | -278 | -180 | -169 | -146 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -355 | -232 | -122 | -140 | -82 |
Depreciation & Amortization (Cash Flow) | 33 | 35 | 40 | 36 | 55 |
Income After Depreciation & Amortization | -388 | -267 | -162 | -176 | -137 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 74.27 | 63.76 | 59.83 | 47.54 | 42.34 |
Diluted EPS Before Non-Recurring Items | -5.07 | -4.37 | -3.01 | -3.56 | -3.46 |
Diluted Net EPS (GAAP) | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 |
Fiscal Year end for Travere Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | -8.55 | 37.10 | 59.70 | 56.99 |
Cost Of Goods | NA | 3.05 | 1.29 | 1.99 | 5.13 |
Gross Profit | NA | -11.59 | 35.81 | 57.71 | 51.87 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 106.54 | 128.39 | 145.29 | 138.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -118.13 | -92.58 | -87.58 | -87.04 |
Non-Operating Income | NA | 8.53 | 6.18 | 4.93 | 3.73 |
Interest Expense | NA | 2.66 | 2.82 | 2.91 | 2.94 |
Pretax Income | NA | -115.06 | -89.23 | -85.57 | -86.25 |
Income Taxes | NA | 0.07 | 0.01 | 0.07 | 0.08 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -115.13 | -89.24 | -85.63 | -86.33 |
Extras & Discontinued Operations | NA | 24.96 | 239.98 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -90.17 | 150.74 | -85.63 | -86.33 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 76.48 | 76.31 | 76.00 | 68.17 |
Diluted EPS Before Non-Recurring Items | NA | -1.16 | -1.17 | -1.13 | -1.27 |
Diluted Net EPS (GAAP) | NA | -1.07 | 1.97 | -1.13 | -1.27 |